2024年5月16日，苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司" 或"麦迪科技"）召开第四届董事会第十九次会议和第四届监事会第九次会议， 审议通过了《关于使用部分闲置募集资金临时补充流动资金的议案》，同意公司 使用总额不超过20,000万元的闲置募集资金暂时补充流动资金，使用期限为自公 司董事会审议批准之日起不超过12个月，到期归还至相应募集资金专用账户。具 体内容详见公司于2024年5月17日披露的《麦迪科技关于使用部分闲置募集资金 临时补充流动资金的公告》（公告编号：2024-051）。 证券代码：603990 证券简称：麦迪科技 公告编号：2025-018 苏州麦迪斯顿医疗科技股份有限公司 关于提前归还临时补充流动资金的募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 在使用募集资金暂时补充流动资金期间，公司严格按照《上市公司监管指引 第2号—上市公司募集资金管理和使用的监管要求》和《上海证券交易所上市公 司自律监管指引第1号——规范运作》《公司募集资金管理及使用制度》等相关 规定，对资金进行合理安 ...

Core Viewpoint - The company, Suzhou Mediston Medical Technology Co., Ltd., is focused on providing clinical medical management information systems and solutions, with a strong emphasis on technological innovation and market expansion in the healthcare sector [2]. Group 1: Company Overview - Mediston specializes in Clinical Information Systems (CIS) and has developed the DoCare series, which serves critical areas such as operating rooms and emergency services [2]. - The company operates in 32 provinces and municipalities across China, serving over 2,400 medical institutions, including nearly 1,200 tertiary hospitals [2]. - Mediston is recognized as a national high-tech enterprise with nearly 600 intellectual property rights and has participated in significant national projects related to digital healthcare [2]. Group 2: Financial Performance - For the third quarter of 2024, the company reported a revenue of 360 million yuan, representing a year-on-year increase of 2.93% [3]. - The net profit for the same period was a loss of approximately 167.22 million yuan, reflecting a year-on-year decline of 81.64% [3]. - The gross profit margin for the company stood at 12.87% [3]. Group 3: Market Position and Valuation - As of April 16, the company's stock closed at 12.71 yuan, down 1.55%, with a price-to-earnings (P/E) ratio of -11.30 and a price-to-book (P/B) ratio of 4.25, leading to a total market capitalization of approximately 3.893 billion yuan [1][4]. - The average P/E ratio in the industry is significantly higher at 138.19, indicating that Mediston's valuation is below industry standards [4].

二、《募集资金专户存储四方监管协议》的签订情况和募集资金专户的开立情况 为规范公司募集资金管理，提高募集资金使用效率，切实保护投资者权益， 根据有关法律法规及《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》等相关规定，2025 年 4 月 14 日，麦迪科技与苏州优麦机器人有限责任公司、 浙商银行股份有限公司苏州分行、申万宏源证券承销保荐有限责任公司（保荐人） 签署了《募集资金专户存储四方监管协议》，前述协议的内容与上海证券交易所 制定的《募集资金专户存储三方监管协议（范本）》不存在重大差异。截至本公 告披露日，募集资金专户开立情况如下： | 账户名称 | 开户银行 | 募集资金专户账号 | 截至本公 | 募集资金 | | --- | --- | --- | --- | --- | | | | | 告披露日 | 用途 | | | | | 账户余额 | | | | | | （万元） | | | 苏州麦迪 | 中国民生银 | 632485373 | 0.29 | 区域急危 | | 斯顿医疗 | 行股份有限 | | | 重症协同 | | 科技股份 | 公司太仓支 | | | 救治系统 | | 有限公司 ...

Core Viewpoint - The company, Suzhou Medistone Medical Technology Co., Ltd., is facing financial challenges with a significant net loss reported in the latest quarterly results, despite a slight increase in revenue. The stock has also seen a decline in value, indicating potential investor concerns. Company Overview - Suzhou Medistone specializes in providing Clinical Information Systems (CIS) and overall clinical information solutions, with its core product, the DoCare series, covering critical areas such as operating rooms and emergency services [2] - The company serves over 2,400 medical institutions across 32 provinces in China, including nearly 1,200 tertiary hospitals, showcasing its extensive market reach [2] - Medistone is recognized as a national high-tech enterprise with a strong emphasis on technological innovation, holding nearly 600 intellectual property rights [2] Financial Performance - For the third quarter of 2024, the company reported a revenue of 360 million yuan, reflecting a year-on-year increase of 2.93% [3] - The net profit for the same period was a loss of approximately 167.22 million yuan, representing a year-on-year decline of 81.64% [3] - The gross profit margin stood at 12.87%, indicating challenges in maintaining profitability [3] Market Position - The company's stock closed at 11.02 yuan, down 7.00%, with a latest price-to-book ratio of 3.68 and a total market capitalization of 3.375 billion yuan [1] - The company is compared to industry averages, with a trailing PE ratio of -9.80, indicating negative earnings, contrasting with the industry average of 130.24 [4]

Company Overview - Suzhou Mediston Medical Technology Co., Ltd. specializes in providing Clinical Information System (CIS) software and overall clinical information solutions, focusing on key areas such as operating rooms, intensive care units, pre-hospital emergency care, and in-hospital emergency services [2] - The company's core product, the DoCare series, leverages advanced mobile internet, IoT technology, and big data models to enhance its competitive edge and professionalism, catering to the high-quality development needs of hospitals in the new era [2] - Mediston's end-users include over 2,400 medical institutions across 32 provinces, autonomous regions, and municipalities, with nearly 1,200 being tertiary hospitals [2] Financial Performance - For the third quarter of 2024, the company reported revenue of 360 million yuan, a year-on-year increase of 2.93%, while net profit was -167.22 million yuan, reflecting a year-on-year decline of 81.64% [3] - The gross profit margin for the company stood at 12.87% [3] Market Position - As of April 1, the company's stock closed at 13.18 yuan, up 1.85%, with a latest price-to-book ratio of 4.40 and a total market capitalization of 4.037 billion yuan [1] - The number of shareholders increased to 29,893, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] Industry Context - The company is recognized as a national high-tech enterprise and has established a provincial technology center, emphasizing technological innovation with nearly 600 intellectual property rights [2] - Mediston has undertaken significant national projects, including the "12th Five-Year" 863 program on digital medical engineering and various innovation tasks from the Ministry of Industry and Information Technology [2] - The company aims to lead in the domestic health care AI sector by exploring the application of cutting-edge technologies such as 5G, IoT, and AI models in low-altitude economic scenarios [2]

3月28日，麦迪科技今日收盘13.02元，下跌2.54%，最新市净率4.35，总市值39.88亿元。 最新一期业绩显示，2024年三季报，公司实现营业收入3.60亿元，同比2.93%；净利润-167220784.71 元，同比-81.64%，销售毛利率12.87%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)75麦迪科技-11.57-14.804.3539.88亿行业平均 118.88120.408.37118.55亿行业中值79.1280.933.9755.78亿1创业慧康-4953.64261.792.0796.05亿2国新健 康-4912.60-135.047.75107.75亿3汇金科技-3691.302678.2922.34140.10亿4拓维信 息-2116.94787.7713.66354.21亿5观想科技-1977.19-1845.504.8238.48亿6安硕信息-1066.65- 161.9020.0974.52亿7光庭信息-559.86-285.552.2044.16亿8数字人-438.34-438.347.6518.23亿9数字政 通-395.8180.932.74108. ...

重要内容提示： | 股东名称 | 傅洪 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | □是 | √否 | | | 董事、监事和高级管理人员 | □是 | √否 | | | 其他：特定股东 | | | | 持股数量 | 3,045,714 股 | | | 一、减持主体减持前基本情况 1 证券代码：603990 证券简称：麦迪科技 公告编号：2025-016 苏州麦迪斯顿医疗科技股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 披露的减持时间区间届满 | 股东名称 | 傅洪 | | --- | --- | | 减持数量 | 749,800 股 | | 减持期间 | 2024 年 12 月 26 日～2025 年 3 月 25 日 | | 减持方式及对应减持数 量 | 集中竞价减持，749,800 股 | | 减持价格区间 | 10.70～17.04 元/股 | | ...

证券代码：603990 证券简称：麦迪科技 公告编号：2025-015 苏州麦迪斯顿医疗科技股份有限公司 关于注销部分募集资金理财专用结算账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 28 日召开第四届董事会第十八次会议、第四届监事会第八次会议，审议通过了《关 于使用部分闲置募集资金进行现金管理的议案》，同意公司在确保不影响募集资 金投资项目进度和募集资金安全的前提下，对暂时闲置的部分募集资金不超过人 民币 3 亿元（包含本数）进行现金管理，余额在上述额度内，资金可以滚动使用， 用于购买单笔期限最长不超过 12 个月（含 12 个月）的结构性存款等安全性高的 保本型产品，不得用于证券投资。公司董事会、监事会及保荐机构已分别对前述 事项发表了同意的意见。具体内容详见公司于 2024 年 4 月 30 日披露的《关于使 用部分闲置募集资金进行现金管理的公告》(公告编号：2024-036)。 截至本公告披露日，公司在浦发银行苏州分行、苏州银行 ...

证券代码：603990 证券简称：麦迪科技 公告编号：2025-014 苏州麦迪斯顿医疗科技股份有限公司 关于公司股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 经公司自查并与公司控股股东及实际控制人进行核实，就有关情况说明如下： （一）生产经营情况 经公司自查，公司目前生产经营情况正常，基本面未发生重大变化，内 外部经营环境未发生重大调整。公司不存在应披露而未披露的重大信息。 （二）重大事项情况 经公司自查，并向公司控股股东绵阳皓祥控股有限责任公司及实际控制 人绵阳市安州区国有资产监督管理办公室函证核实，截止本公告披露日，除 在指定媒体上已公开的信息外，不存在其他涉及公司的应披露而未披露的重 大信息，包括但不限于重大资产重组、发行股份、重大交易类事项、股份回 购、股权激励、重大业务合作、破产重组、业务重组、引入战略投资人等重 大事项。 重要内容提示： 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）股票于 2025 年 2 月 13 日、2 月 14 日、2 月 17 日连续三个交易日内收盘价格涨 ...

苏州菱迪斯顿医疗科技股份有限公司: 本公司作为公司的控股股东已收到公司发来的《关于苏州麦迪斯顿医疗科 技股份有限公司股票异常波动问询函》,经自查确认,现回复如下: 一、 截至目前,除了在指定媒体上已公开披露的信息外,本公司不存在 涉及贵公司的应予以披露而未披露的重大信息,包括但不限于重大资产重组、 股份发行、重大交易类事项,业务重组、股份回购、股权激励、破产重整、重 大业务合作,引进战略投资者等重大事项。 二、在本次股票交易异常波动期间,本公司不存在买卖贵公司股票的情 形。 特此回复, 关于苏州麦迪斯顿医疗科技股份有限公司股票交易异常波动的回函 关于苏州麦迪斯顿医疗科技股份有限公司股票交易异常波动的回函 苏州麦迪斯顿医疗科技股份有限公司: 本单位作为公司的实际控制人已收到公司发来的《关于苏州麦迪斯顿医疗 科技股份有限公司股票异常波动问询函》,经自查确认,现回复如下; 一、 载至目前,除了在指定媒体上已公开披露的信息外,本单位不存在 涉及贵公司的应予以披露而未披露的重大信息,包括但不限于重大资产重组、 股份发行、重大交易类事项、业务重组、股份回购、股权激励、破产重整、重 大业务合作、引进战略投资者等重大事项。 ...